Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses dose levels of cetuximab (Erbitux) in patients with head and neck cancer.
Joseph Ciccolini, PhD
Advertisement
Articles by Joseph Ciccolini, PhD
Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses investigating the residual concentrations of other agents for the treatment of patients with head and neck cancer.
Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses residual concentrations of cetuximab (Erbitux) in patients with head and neck cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
Innovative Screening Approaches, Targeted Therapies, and Team-Based Care Drive Head and Neck Oncology Advances
3
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
4
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
5